Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 7, 2012, Pages 1101-1108

  John, Thomas ^a   Yanagawa, Naoki ^b   Kohler, Derek ^b   Craddock, Kenneth J ^b   Bandarchi Chamkhaleh, Bizhan ^b   Pintilie, Melania ^c   Sykes, Jenna ^c   To, Christine ^c   Li, Ming ^b   Panchal, Devang ^b   Chen, Weisan ^a   Shepherd, Frances A ^a,d   Tsao, Ming Sound ^a,d  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Lymphoma; Non Small Cell Lung Cancer; Primary tumor xenograft; Survival

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PROTEIN BCL 2; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84862900764     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182519d4d     Document Type: Article

References (33)

1. John T, Kohler D, Pintilie M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2011;17:134-141.
2. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008;14:6456-6468.
3. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009;101:6-8.
4. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003;2(4 Suppl 1):S134-S139.
5. Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 2009;36:454-459.
6. Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol 2008;65:200-211. (Pubitemid 351174052)
7. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
8. Stanbredge EJ, Boulger LR, Franks CR, et al. Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed mice. Cancer Res 1975;35:2203-2212.
9. Monticello TM, Green DS, Yang H, Drain RL, Franco CT, Durham SK. Spontaneous thymic lymphoma in severe combined immunodeficiency (SCID) mice engrafted with human peripheral blood lymphocytes. Ve t Pathol 1994;31:393-395.
10. Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci USA 1992;89:3290-3294.
11. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111. (Pubitemid 32391043)
12. Ruckdeschel JC, Codish SD, Stranahan A, McKneally M F. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972;287:1013-1017.
13. Wei YQ Hang ZB. In situ observation of lymphocyte-tumor cell interaction in human lung carcinoma. Immunol Invest 1989;18:1095-1105.
14. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-4417.
15. Pine SR, Mechanic LE, Ambs S, et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007;99:1401-1409. (Pubitemid 351767188)
16. Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2010;28:7531.
17. Shepherd FA, Douillard J Y, Blumenschein GR Jr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol 2011;6:1763-1773.
18. Travis WD, Brambilla E, Muller-Hermelin HK, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
19. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors (UICC Internationl Union Against Cancer), 7th Ed. Lyon, France: Wiley-Blackwell, 2009.
20. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144. (Pubitemid 41058345)
21. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-351. (Pubitemid 46328493)
22. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
23. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-1010.
24. Abe T, Tada M, Shinohara N, et al. Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. Int J Urol 2006;13:47-57.
25. Gan R, Xie X, He J, et al. Gene analysis of Epstein-Barr virus-associated lymphomas in Hu-Pbl/SCID chimeras. Tumori 2010;96:465-472.
26. Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, et al. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol 2004;78:13891-13900. (Pubitemid 39612786)
27. Bankert RB, Egilmez NK, Hess SD. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 2001;22:386-393. (Pubitemid 32673645)
28. Young LS Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-768. (Pubitemid 39331148)
29. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 1992;66:122-131.
30. Bharadwaj M, Sherritt M, Khanna R, Moss DJ. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design. Vaccine 2001;19:3769-3777. (Pubitemid 32522776)
31. Moss DJ, Misko IS, Burrows SR, Burman K, McCarthy R, Sculley TB. Cytotoxic T-cell clones discriminate between A-and B-type Epstein-Barr virus transformants. Nature 1988;331:719-721. (Pubitemid 18062239)
32. Bradbury PA Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008;3(6 Suppl 2):S164-S170. (Pubitemid 351786751)
33. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.